Baike Biotechnology (688276.SH): Clinical trial application for recombinant herpes zoster vaccine (CHO cells) approved

Zhtng Cijng APP News, Bakel Biotechnology (688276.SH) announced that the company recently received the "Drug Clinical Trial Approval Notification" of the recombinant herpes zoster vaccine (CHO cells) issued by the National Medical Products Administration.